Navigation Links
Pharmion and Methylgene Report Favorable Results for Phase 2 MGCD0103 Single- Agent Studies in Relapsed or Refractory Lymphomas at the 49th American Society of Hematology (ASH) Meeting
Date:12/9/2007

- MGCD0103 Continues to Demonstrate Single-Agent Activity - 38% Response Rate, 43% Disease Control Rate and 86% Tumor Reduction Rate in Heavily-Pretreated Patients with Relapsed or Refractory Hodgkin Lymphoma

in 110mg Cohort - 67% Tumor Reduction Rate in Relapsed or Refractory Non-Hodgkin Lymphoma, Including an 18% Response Rate in Evaluable Diffuse Large B- cell Patients

ATLANTA, Dec. 9 /PRNewswire-FirstCall/ -- Pharmion Corporation (Nasdaq: PHRM) and MethylGene Inc. (TSX: MYG) today announced data from two ongoing Phase 2 studies with MGCD0103, the Companies' novel, isotype-selective histone deacetylase (HDAC) inhibitor, as a single-agent in the treatment of Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). Data from these studies were presented today at the 49th Annual Meeting and Exposition of the American Society of Hematology (ASH).

"These exploratory Phase 2 trials show meaningful activity of MGCD0103 in patients with differing types of lymphomas," said Patrick J. Mahaffy, president and chief executive officer of Pharmion. "This is important not only for the continuing development of MGCD0103 but also because it provides further evidence for the role of epigenetic therapies in the treatment of hematologic malignancies."

"Data from these most recent trials continue to demonstrate the single- agent potential for MGCD0103 in a patient population that currently has few effective therapeutic options," said Donald F. Corcoran, president and chief executive officer of MethylGene. "With our partners, we will continue to evaluate our current and near-term MGCD0103 clinical trials during 2008 with the goal to develop a potential registrational pathway."

Isotype Selective HDAC Inhibitor MGCD0103 Decreases Serum TARC Concentrations and Produces Clinical Responses in Heavily Pretreated Patients with Relapsed Classical Hodgkin lymphoma (HL), Abstract #2566 (Trial 010)

To date, 33 patients
'/>"/>

SOURCE Pharmion Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Pharmion and GPC Biotech Announce Results of Overall Survival Analysis From the Satraplatin Pivotal Phase 3 Trial
2. Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology (ASH) Annual Meeting
3. Virginia Tech Report Has National Importance
4. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
5. GAO Report Confirms: Medicare Underpays for Anesthesia Services; Nurse Anesthetists Assure Seniors Access to Safe Anesthesia Care
6. Haemacure Reports Third Quarter 2007 Results
7. Report on patients access to cancer drugs uses flawed methods to reached flawed conclusions
8. Biotech Finishes on a High in August, Burrill Report Says
9. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
10. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
11. MDS Reports Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... PLOS Pathogens , children who live in regions of ... immune response to infection with malaria parasites that may ... and illness and partially control the growth of malaria ... develop future interventions that prevent or mitigate the disease ... 200 million cases of malaria occur worldwide, resulting in ...
(Date:4/17/2014)... a review published in the April issue of ... Feinstein Institute for Medical Research, says it,s time to ... approach to treating sepsis, which kills millions worldwide ... occurs when molecules released into the bloodstream to fight ... Inflammation is necessary for maintaining good health without ...
(Date:4/17/2014)... 17, 2014) Doctors who treat patients with ... (LAM) can face an agonizing treatment decision. , ... disease and help relieve shortness of breath. But ... sirolimus can cause potentially fatal complications following transplantation. ... Daniel Dilling, medical director of Loyola University Medical ...
(Date:4/17/2014)... a new mechanism that allows blood to enter the ... and the Salk Institute have opened the door to ... damage. , A complex and devastating neurological condition, stroke ... for disability in the U.S. The blood-brain barrier is ... into the brain, causing the permanent deficits in movement ...
(Date:4/17/2014)... potential to ward off depression among retirees, particularly among ... in The Journals of Gerontology, Series B: ... article " Internet Use and Depression Among Retired Older ... the authors report that Internet use reduced the probability ... study sample. , Late-life depression affects between 5 ...
Breaking Medicine News(10 mins):Health News:Study sheds light on how the immune system protects children from malaria 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:Study IDs new cause of brain bleeding immediately after stroke 2Health News:Internet use may cut retirees' depression 2
... study in the May 1 issue of the journal SLEEP ... sample of exceptionally old adults, including nearly 2,800 people who were ... 65 percent of the sample reported that their sleep quality was ... was about 7.5 hours including naps. Surprisingly, the ...
... ... releases statement on Intellectual Property Day , ... (PRWEB) April 30, 2010 -- Ranjit Shahani, President of the Organization ... the effect drug patent protection is having on innovation in India: , , ,Emotion tends ...
... say C. gattii not infecting as many as ... News) -- The new "killer" fungus spreading through the Pacific ... , "It,s definitely real in that we,ve been seeing this ... lot more meningitis than you would expect in the general ...
... ... designed for any athlete requiring therapy for fatigued or overused shoulder and elbows. ... Dallas, TX (PRWEB) May 2, ... for fatigued or overused shoulder and elbows. This great new product was named Best of ...
... had no adverse effects, researchers say , FRIDAY, April ... and Flumadine appear to be safe for pregnant women ... analyzed the medical records of 239 pregnant women who ... with one of the three drugs. Among these patients, ...
... in running, catching, throwing lead to sedentary lifestyle, study ... than three-quarters of disadvantaged preschool children in the United ... running, jumping, throwing and catching, a new study finds. ... giving up on physical activity and becoming obese teens ...
Cached Medicine News:Health News:Sleeping well at 100 years of age: Study searches for the secrets to healthy longevity 2Health News:Drug Patents in India Helping Promote Innovation 2Health News:Drug Patents in India Helping Promote Innovation 3Health News:'Killer' Fungus Not So Deadly 2Health News:'Killer' Fungus Not So Deadly 3Health News:Chilly-Billy Ice Compress - Arm Care for Athletes 2Health News:Chilly-Billy Ice Compress - Arm Care for Athletes 3Health News:Taking Flu Drugs While Pregnant Appears to Be Safe: Study 2Health News:Motor Skills Lag in Poor Preschoolers 2
(Date:1/15/2014)... GARDENS, Fla. , Jan. 15, 2014  In an unprecedented effort ... and TB in ambulances and other transport vehicles, an advanced and ... by rescue personnel for the first time. In ... contact with these deadly pathogens, West Palm Beach ...
(Date:1/15/2014)... , Jan. 15, 2014  According to Millennium Research ... market intelligence, the United States ... device markets will expand moderately through 2022, with ... In particular, increasing interest in drug-eluting beads (DEBs) ...
(Date:1/15/2014)... NEW YORK , Jan. 15, ... new market research report is available ... Global Markets and Technologies for ... on Routes of Administration ...
Breaking Medicine Technology:Superbugs No Longer Ride In Rescue Vehicles 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16
... 8, 2011 Ness County Hospital is moving ... the implementation of Prognosis ChartAccess® Comprehensive EHR, the ... federal government,s meaningful use requirements as stipulated under ... At the same time, the Ness ...
... Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN ) will ... Tuesday, February 15, 2011.  The presentation is scheduled for ... through the Company,s web site, www.regeneron.com , on ... presentation will be available after the live webcast through ...
Cached Medicine Technology:Ness County Hospital Selects ChartAccess® Comprehensive EHR from Prognosis Health Information Systems 2Ness County Hospital Selects ChartAccess® Comprehensive EHR from Prognosis Health Information Systems 3
Inquire...
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
Inquire...
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
Medicine Products: